Explanipedia

Predictors of mortality among critically ill SARS-CoV-2 infected patients—a retrospective cohort study, Kerala, India Open

Anil Sathyadas, Aravind Reghukumar, Thekkumkara Surendran Anish, Gnanaseelan Kanakamma Libu, V. Kiran , et al. · 2025

Background Preventing the in-hospital mortality of critically ill patient is the last opportunity to saves lives during a pandemic. It was a need for the hospital settings of global south to further prioritize the individuals in this vulne…

The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients Open

Shohei Mizuno, Luuk Gras, Laurien Baaij, Linda Köster, Anita D’Souza , et al. · 2025

Despite the availability of novel agents, autologous hematopoietic cell transplantation (auto-HCT) remains the standard of care in newly diagnosed multiple myeloma (MM) patients. The impact of age on overall survival (OS), progression-free…

Current Use of and Trends in Hematopoietic Cell Transplantation in the United States Open

Anita D’Souza, Caitrin Fretham, Stephanie J. Lee, Mukta Arora, Janet Brunner , et al. · 2025

Corrigendum to ‘Current Use and Trends in Hematopoietic Cell Transplantation in the United States’ [Transplantation and Cellular Therapy 26/8 (2020) e177-e182] Open

Anita D’Souza, Caitrin Fretham, Stephanie J. Lee, Mukta Arora, Janet Brunner , et al. · 2025

Allogeneic versus autologous stem cell transplantation after relapsing following first line autologous transplantation for multiple myeloma: A systematic review Open

Heinz Ludwig, Sarah Bernhard, Takashi Ikeda, César O. Freytes, Martin Schreder , et al. · 2025

Background Allogeneic stem cell transplantation (allo‐SCT) has curative potential and was previously considered by several experts superior to autologous stem cell transplantation (auto‐SCT) for patients with multiple myeloma relapsing aft…

Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real‐world data Open

Noa Biran, Binod Dhakal, Rubén Niesvizky, Suzanne Lentzsch, Divaya Bhutani , et al. · 2025

Summary Over the years, numerous prognostic markers for multiple myeloma (MM) risk classification have been identified; however, their variability can lead to inconsistent clinical interpretations. Gene expression profiling (GEP) signature…

Platelet-Targeted Gene Therapy for Hemophilia A with Inhibitor History Open

Mary Eapen, Lynn Malec, Myriam Armant, Bryon D. Johnson, Qizhen Shi , et al. · 2025

Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma Open

Binod Dhakal, Parameswaran Hari, Saurabh Chhabra, Anikó Szabó, Lawrence G. Lum , et al. · 2025

Background Polyclonal autologous T cells that are epigenetically reprogrammed through mTOR inhibition and IFN-α polarization (RAPA-201) represent a novel approach to the adoptive T cell therapy of cancer. Ex vivo inhibition of mTOR results…

Novel Gene expression-based Risk Stratification tool predicts recurrence in Non-muscle invasive Bladder cancer Open

N Srivatsa, Parameswaran Hari, P. Patel Rahul, Lista Paul, Durgadevi Veeraiyan , et al. · 2024

Bladder cancer is a heterogeneous disease that has a very unique challenge in treatment and management. The disease at the start could be indolent and slow growing and display low potential for further progression to muscle-invasive. Once …

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk Open

Natalie S. Callander, Rebecca Silbermann, Jonathan L. Kaufman, Kelly N. Godby, Jacob P. Laubach , et al. · 2024

Randomized Phase III SIERRA Trial of <sup>131</sup> I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML Open

Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R. Litzow , et al. · 2024

PURPOSE Older patients with relapsed or refractory AML (RR AML) have dismal prognoses without allogeneic hematopoietic cell transplantation (alloHCT). SIERRA compared a targeted pretransplant regimen involving the anti-CD45 radioconjugate …

Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (<span>WBMT</span>) Open

Laurent Garderet, Luuk Gras, Linda Köster, Laurien Baaij, Nada Hamad , et al. · 2024

Autologous hematopoietic cell transplantation (AHCT) is a commonly used treatment in multiple myeloma (MM). However, real‐world global demographic and outcome data are scarce. We collected data on baseline characteristics and outcomes from…

Clinical and economic burden of medicare beneficiaries with multiple myeloma and renal impairment: An observational study Open

Parameswaran Hari, Dominick Latremouille‐Viau, Peggy L. Lin, Annie Guérin, Medha Sasané · 2024

Evidence on real-world clinical and economic outcomes in patients with multiple myeloma (MM) and renal impairment (RI) is limited in the United States. This retrospective study aimed to generate an updated comprehensive assessment of the c…

Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival Open

Marcelo C. Pasquini, Paul K. Wallace, Brent R. Logan, Manmeet Kaur, Joseph D. Tario , et al. · 2024

PURPOSE Prognostic Immunophenotyping in Myeloma Response (PRIMeR) is an ancillary study of minimal residual disease (MRD) assessment for multiple myeloma by next-generation multiparameter flow cytometry (MFC). Patients were enrolled on a t…

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk Open

Natalie S. Callander, Rebecca Silbermann, Jonathan L. Kaufman, Kelly N. Godby, Jacob P. Laubach , et al. · 2024

In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomid…

Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing Open

Jianrong Li, Shahram Arsang‐Jang, Yan Cheng, Fumou Sun, Anita D’Souza , et al. · 2024

Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial Open

Ehsan Malek, Jeries Kort, Leland Metheny, Pingfu Fu, Gen Li , et al. · 2024

Identification of novel loci for multiple myeloma when comparing with its precursor condition monoclonal gammopathy of unknown significance Open

Christopher Staffi Buradagunta, Shahram Arsang‐Jang, Ben Massat, Bicky Thapa, Anita D’Souza , et al. · 2023

Novel Therapies in Cancer: Summit on Cancer Health Disparities, Keynote and Panel Discussion Open

Mehndi Dandwani, Mark D. Pegram, Jerry Radich, Lidia Schapira, Manali I. Patel , et al. · 2023

Molecularly-targeted therapeutics play a pivotal role in the therapeutic arena in cancer medicine, in many cases prolonging overall survival. However, despite decades since their foray into the cancer therapy armamentarium, many targeted t…

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial Open

Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai Dholaria, Timothy M. Schmidt , et al. · 2023

Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial Open

Ehsan Malek, Jeries Kort, Leland Metheny, Pingfu Fu, Parameswaran Hari , et al. · 2023

AML-521 The Randomized Phase III SIERRA (Study of Iomab-B in Elderly Relapsed or Refractory AML) Trial: Successful Allogeneic Hematopoietic Stem Cell Transplantation Using Treatment With Iomab-B-Led Regimen for Patients With Active, Relapsed or Refractory AML With Failed Targeted Therapies Open

Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R. Litzow, Camille N. Abboud , et al. · 2023

S248: SIERRA TRIAL RESULTS WITH A TARGETED RADIOTHERAPY, IOMAB-B, A MYELOABLATIVE CONDITIONING WITH REDUCED INTENSITY TOLERABILITY YIELDS HIGH CR, LONG TERM SURVIVAL IN HSCT INELIGIBLE ACTIVE R/R AML Open

Boglarka Gyurkocza, Stuart Seropian, Hannah Choe, Mark R. Litzow, Camille N. Abboud , et al. · 2023

Background: Despite recent advances in the treatment of acute myeloid leukemia (AML), prognosis for patients with relapsed, refractory (R/R) disease remains poor. The only potentially curative option for these patients is allogeneic hemato…

S203: QUADRUPLET INDUCTION THERAPY, ASCT AND MRD-MODULATED CONSOLIDATION AND TREATMENT CESSATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL ANALYSIS OF THE MASTER TRIAL Open

Luciano J. Costa, Eva Medvedova, Sarabh Chhabra, Bhagirathbhai Dholaria, Binod Dhakal , et al. · 2023

Background: Quadruplet therapy increases the depth and duration of response in newly diagnosed multiple myeloma (NDMM) patients. In patients receiving same therapy in the context of clinical trials, the achievement of minimal residual dise…

P1082: RESULTS FROM A PHASE 1/2 STUDY OF TANDEM, BISPECIFIC ANTI-CD20/ANTI-CD19 (LV20.19) CAR T-CELLS FOR MANTLE CELL LYMPHOMA Open

Nirav N. Shah, Timothy S. Fenske, Bryon D. Johnson, Anikó Szabó, Sumana Devata , et al. · 2023

Topic: 18. Indolent and mantle-cell non-Hodgkin lymphoma - Clinical Background: Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy characterized by presence of t(11;14) and bright CD20 expression. Approved CD19 CAR T-cell therap…

Impact of Baseline and Week 2 and Week 4 Posttransplant CMV Cell-Mediated Immunity on Risk of CMV Infections and Mortality in Recipients of Allogeneic Hematopoietic Cell Transplant Open

Ella Ariza‐Heredia, Drew J. Winston, Scott D. Rowley, Kathleen M. Mullane, Pranatharthi Chandrasekar , et al. · 2023

Background Cytomegalovirus (CMV) infection is a common opportunistic infection after allogeneic hematopoietic cell transplant (alloHCT). We explored whether a change in CMV cell-mediated immunity during the first month after transplant pre…

Protracted viral infections in patients with multiple myeloma receiving bispecific T-cell engager therapy targeting B-cell maturation antigen Open

Breanna Palmen, Parameswaran Hari, Anita D’Souza, Muhammad Bilal Abid · 2023

Recent expansion in therapeutic landscape in multiple myeloma (MM) has resulted in significant improvement in patient survival.Specifically, chimeric antigen receptor (CAR) T-cells and bispecific T-cell engagers (BiTEs) targeting B-cell ma…

A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy Open

Ariel Kleman, Arun Singavi, Lauren Pommert, Angela Mathison, Parameswaran Hari , et al. · 2023

Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study Open

Binod Dhakal, Mei-Jei Zhang, Linda J. Burns, Xiaoying Tang, Christa L. Meyer , et al. · 2023

Not available.

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study Open

Jason Chesney, Karl D. Lewis, Harriet M. Kluger, Omid Hamid, Eric D. Whitman , et al. · 2022

Background Patients with advanced melanoma have limited treatment options after progression on immune checkpoint inhibitors (ICI). Lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, demonstrated an investig…

Parameswaran Hari YOU? Author Swipe